A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuschlar Oncaspar in Pediatric patients with relapsed cased of Acute Lymphoblastic Leukemia

Trial Profile

A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuschlar Oncaspar in Pediatric patients with relapsed cased of Acute Lymphoblastic Leukemia

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Pegaspargase (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Pharmacokinetics
  • Sponsors Gennova Biopharmaceuticals
  • Most Recent Events

    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top